文献速递淋巴瘤造血干细胞移植与细胞治疗

肾功能下降预测大B细胞淋巴瘤CAR-T治疗后重度细胞因子释放综合征

Decreased renal function predicts severe cytokine release syndrome after CAR-T-cell therapy for large B-cell lymphoma.
PubMed 文献 · Br J Haematol · 2026-04-15

该回顾性研究基于日本全国登记数据库,分析2019至2024年接受CD19 CAR-T治疗的900例大B细胞淋巴瘤患者,发现输注后30天内任何级别CRS累积发生率为75.0%,≥2级为20.8%,≥3级为14.0%;多变量分析显示较低eGFR、较高铁蛋白、CRP和LDH独立预测≥2级CRS,并据此构建CRS-PRE四因素模型将风险分层为低、中、高组,发生率分别为2.8%、26.0%和50.0%。

要点

  • 900例LBCL患者CAR-T后30天内≥2级CRS累积发生率为20.8%,≥3级为14.0%。
  • 较低eGFR、较高铁蛋白、CRP和LDH是≥2级CRS的独立预测因素。
  • CRS-PRE模型将≥2级CRS风险分为低、中、高组,发生率分别为2.8%、26.0%和50.0%。

核心结论

  • 肾功能下降(较低eGFR)联合铁蛋白、CRP和LDH升高可预测LBCL患者CAR-T后≥2级CRS。
  • 基于四因素构建的CRS-PRE模型可对≥2级CRS进行风险分层。

研究设计与样本

  • 回顾性分析日本全国登记数据库中2019至2024年接受CD19 CAR-T治疗的900例大B细胞淋巴瘤患者,中位年龄62岁。

主要发现

  • 输注后30天内任何级别CRS累积发生率为75.0%,≥2级为20.8%,≥3级为14.0%。
  • 多变量分析中,eGFR每降低10 mL/min per 1.73 m2的aHR为1.108(95%CI 1.015-1.209;p=0.022)。
  • 铁蛋白每升高100 ng/mL的aHR为1.006(95%CI 1.001-1.010;p=0.016)。
  • CRP每升高1 mg/dL的aHR为1.142(95%CI 1.091-1.195;p<0.001)。
  • LDH每升高100 U/L的aHR为1.073(95%CI 1.008-1.142;p=0.028)。

关键数值与推荐

  • CRS-PRE模型将≥2级CRS风险分为低、中、高组,发生率分别为2.8%、26.0%和50.0%。

临床怎么用

  • CRS-PRE模型或有助于临床对LBCL患者CAR-T治疗后进行风险适配的监测和干预。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Cytokine release syndrome (CRS) remains a major toxicity of chimeric antigen receptor (CAR) T-cell therapy in large B-cell lymphoma (LBCL), and robust pre-infusion predictors are needed for risk-adapted management. We retrospectively analysed LBCL patients in the Japanese nationwide registry who underwent CD19 CAR-T-cell therapy between 2019 and 2024. Among 900 patients (median age 62 years), cumulative incidences of CRS within 30 days after infusion were 75.0% for any grade, 20.8% for grade ≥ 2 and 14.0% for grade ≥ 3. In multivariable analysis, lower estimated glomerular filtration rate (eGFR) (adjusted hazard ratio [aHR] 1.108 per 10 mL/min per 1.73 m2 decrease; 95% confidence interval [CI] 1.015-1.209; p = 0.022), higher ferritin (aHR 1.006 per 100 ng/mL; 95% CI 1.001-1.010; p = 0.016), C-reactive protein (CRP) (aHR 1.142 per mg/dL; 95% CI 1.091-1.195; p < 0.001) and lactate dehydrogenase (LDH) (aHR 1.073 per 100 U/L; 95% CI 1.008-1.142; p = 0.028) independently predicted grade ≥ 2 CRS. We then built a four-factor CRS pre-infusion risk evaluation model, cytokine release syndrome-pre-infusion risk evaluation (CRS-PRE), that stratified grade ≥ 2 CRS risk into low, intermediate and high groups with incidences of 2.8%, 26.0% and 50.0% respectively. Decreased eGFR, a surrogate of host renal reserve, with elevated ferritin, CRP and LDH emerged as predictors of high-grade CRS. The CRS-PRE may facilitate risk-adapted monitoring and intervention in clinical practice.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Arai Y, Jo T, Sato T, et al. Decreased renal function predicts severe cytokine release syndrome after CAR-T-cell therapy for large B-cell lymphoma. Br J Haematol. 2026. PMID: 41986280. doi:10.1111/bjh.70488

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。